Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480)
Health Care · Biotechnology · CN
HK$13.40
-2.90% today · -44.9% 1Y
Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480) operates in the Biotechnology industry within the Health Care sector. The company is valued at $339.67M and employs 193 people.
Over the last twelve months the share price has lost 44.9%, trading between 12.00 and 26.00.
Tweenvest scores Beijing Luzhu Biotechnology Co., Ltd. across four factors: quality 51/100, value 52/100. Its strongest factor is value.
2480 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $339.67M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.68
- Dividend yield
- —
- Beta (5Y)
- -0.61
- 52-week high
- HK$26.00
- 52-week low
- HK$12.00
- Avg volume (3M)
- —
- Shares outstanding
- 198.91M
- Employees
- 193
- Next earnings
- —
About Beijing Luzhu Biotechnology Co., Ltd.
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.
- ISIN
- CNE100005YD8
- Founded
- 2001
- Listed since
- May 8, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.NasdaqGM: ARTV | $342.23M | $6.79 | -3.00% |
| Orum Therapeutics, Inc.KOSDAQ: A475830 | $341.62M | ₩21,150.00 | -15.40% |
| Agenus Inc.NasdaqCM: AGEN | $340.80M | $7.61 | +0.53% |
| 3-D Matrix, Ltd.TSE: 7777 | $340.80M | ¥420.00 | +0.72% |
| Ocugen, Inc.NasdaqCM: OCGN | $339.11M | $0.99 | -0.62% |
| Hansa Biopharma AB (publ)OM: HNSA | $336.45M | Skr33.38 | +0.60% |
| Cabaletta Bio, Inc.NasdaqGS: CABA | $334.00M | $1.92 | -2.54% |
| GC Corp.KOSE: A005250 | $326.61M | ₩9,680.00 | +2.54% |
Figures last refreshed Oct 4, 2026.